Clinical Partnerships PathMaker's clinical-stage non-invasive neuromodulation platform is well positioned for research collaborations and pilot trials with ALS centers and academic medical centers. Pursue co-development and site-based studies to build real-world evidence and establish early adoption pathways.

Public Funding Strong government and foundation support validates the technology and creates entry points for funded trials and hospital procurement conversations within ALS and neurodegenerative research programs.

Target Customers Primary buyers are neurology clinics, ALS centers, and academic medical centers seeking drug-free non-invasive therapeutics for serious neurological disorders. Focus on high-volume centers in major markets to establish case studies and generate payer-ready data.

Leadership Access Engage with PathMaker's board and leadership network to access procurement channels, key opinion leaders, and partnerships with larger medical device companies or distributors, enabling faster pilot deployment and broader market reach.

Commercial Path With near-commercial positioning and aligned grant funding, accelerate market entry through pilot programs, early adopters, and strategic alliances with research networks and hospitals, while building evidence for broader ALS and other indications.